Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Shire PLC    SHP   JE00B2QKY057


Delayed Quote. Delayed  - 10/27 12:34:45 pm
4905.5 GBp   +0.09%
10/24 SHIRE : Powerful Video Gives Voice to the ...
10/19 MERRIMACK PHARM : Shire Granted EU Marketing Authorization of ONIVYD..
10/19 SHIRE : to announce third quarter ...
News SummaryMost relevantAll newsSector news 

Shire Plc. : Shire Buying Pervasis To Advance Regenerative Medicines Business

share with twitter share with LinkedIn share with facebook
share via e-mail
04/12/2012 | 05:49pm CEST
  By Sten Stovall 

Shire PLC (SHP.LN) is buying the assets of U.S.-based Pervasis Therapeutics in a deal that brings a new technology aimed at improving blood vessel repair for dialysis patients to the U.K. drug maker's regenerative medicine business.

A specialist in hyperactivity and rare genetic diseases, Shire is also expanding its activities in regenerative medicine to find products for replacing human cells, tissues or organs to restore or establish normal function.

Toward that end, Shire on Thursday said it will pay Pervasis an undisclosed upfront payment, plus milestones if Pervasis' lead product, a cell-based therapy called Vascugel, hits certain clinical, regulatory and sales targets. No financial terms were disclosed.

Pervasis, based in Cambridge, Massachusetts, is developing acute vascular repair technologies for patients with end-stage renal disease, or ESRD, which is an advanced and irreversible kidney disease. There are around 600,000 people in the U.S. and more than 250,000 in the EU currently being treated for ESRD.

Shire said its deal with Pervasis will make a strong strategic fit with its existing Dermagraft treatment for diabetic foot ulcers.

Diabetes is the chief cause of ESRD, while diabetic patients on dialysis have a greater risk of developing a diabetic foot ulcer than diabetics not receiving dialysis treatment.

Shire's head of regenerative medicine, Kevin Rakin, said that "this acquisition marks a very important step for Shire in building a regenerative medicine business focused on tissue repair and regeneration."

He told Dow Jones Newswires that Vascugel is currently in mid-stage clinical trials and will be progressing to late-stage Phase III testing soon. Vascugel has received Orphan Product designation from the U.S. Food and Drug Administration and from the European Medical Agency. If all goes well, marketing authorization could be sought for Vascugel by 2017, Rakin said.

Pervasis will give Shire a new cell-based technology platform called endothelial cell technology that has global potential. "We are looking at generating other products out of this platform," Rakin said.

"We're building our regenerative medicine activities because we believe it's one of the next big areas of medicine and so this adds to the Dermagraft purchase and we're building up our pipeline now. We're committed to doing this."

- By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SHIRE PLC
10/24 SHIRE : Powerful Video Gives Voice to the ...
10/19 SHIRE PLC : Financial Statements and Exhibits (form 8-K)
10/19 MERRIMACK PHARMACEUTICALS : Shire Granted EU Marketing Authorization of ONIVYDE,..
10/19 SHIRE : to announce third quarter ...
10/18 SHIRE : Announces Update to Vyvanse (lisdexamfetamine dimesylate) U.S. Labeling ..
10/18 SHIRE : Granted EU Marketing ...
10/17 SHIRE : Modern Technology and a ...
10/12 FTSE 100 and FTSE 250 equity indexes lose ground
10/12 SHIRE : *deutsche bank raises shire price target to 6200 pence - 'buy'
10/07 SHIRE : Kamada Announces Extension of GLASSIA Supply and Distribution Agreement ..
More news
Sector news : Pharmaceuticals - NEC
10/26 GLAXOSMITHKLINE : British imports of cheap medicines dry up as pound falls
10/26DJGlaxo Profit Jumps on Weaker Pound
10/26 Bayer third-quarter profit beats forecasts on pharma, pesticides
10/25DJMERCK : Profit Rises on Cancer Drugs, Vaccines
10/25DJMERCK : Revenue and Profit Rise on Cancer Drugs, Vaccines -- Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/24 CTI Bio and Baxalta ink agreement for return of pacritinib
10/19 BIOTECH FORUM DAILY DIGEST : Can Biotech Rebound? Jefferies Says Sector Underval..
10/18 M&A Gives Signs Of Reverting To The Mean
10/18 Encouraging News From Omeros Corporation
10/18 Shire's ONIVYDE OK'd in Europe for pancreatic cancer
Financials ($)
Sales 2016 11 045 M
EBIT 2016 3 810 M
Net income 2016 1 475 M
Debt 2016 20 013 M
Yield 2016 0,49%
P/E ratio 2016 26,69
P/E ratio 2017 14,50
EV / Sales 2016 6,69x
EV / Sales 2017 4,60x
Capitalization 53 929 M
More Financials
Duration : Period :
Shire PLC Technical Analysis Chart | SHP | JE00B2QKY057 | 4-Traders
Full-screen chart
Technical analysis trends SHIRE PLC
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 79,2 $
Spread / Average Target 32%
Consensus details
EPS Revisions
More Estimates Revisions
Flemming Ornskov Chief Executive Officer & Executive Director
Susan Saltzbart Kilsby Non-Executive Chairman
Jeffrey Poulton Chief Financial Officer & Executive Director
Philip J. Vickers Global Head-Research & Development
David R. Ginsburg Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SHIRE PLC4.32%53 929
JOHNSON & JOHNSON11.53%313 422
ROCHE HOLDING LTD.-17.44%196 913
PFIZER INC.0.37%196 527
NOVARTIS AG-16.42%188 199
MERCK & CO., INC.15.24%168 318
More Results